return to news
  1. Ujin Pharma files draft papers with SEBI for IPO

Market News

Ujin Pharma files draft papers with SEBI for IPO

Journalist Kamal Joshi, former Republic TV and latestly news editor, currently associated with Upstox as senior ipo writer.

2 min read | Updated on June 23, 2026, 13:32 IST

SUMMARY

The proposed initial share sale of Ujin Pharma is a combination of fresh issuance of 11,869,100 shares and an offer for sale (OFS) of 7,282,300 shares by promoters Umang Ketan Mehta and Jinesh Rasiklal Sheth, as per the draft red herring prospectus.

Ujin Pharma is involved in distribution and supply of a diversified portfolio of speciality chemicals, solvents, acids, monomers, pharmaceutical raw materials and nutraceuticals. | Image: ujinpharma.com

Ujin Pharma is involved in distribution and supply of a diversified portfolio of speciality chemicals, solvents, acids, monomers, pharmaceutical raw materials and nutraceuticals. | Image: ujinpharma.com

Chemical importing and distribution company Ujin Pharma has filed preliminary papers with market regulator Securities and Exchange Board of India (SEBI) to raise funds via an initial public offering.

Open FREE Demat Account within minutes!
Join now

The proposed initial share sale is a combination of fresh issuance of 11,869,100 shares and an offer for sale (OFS) of 7,282,300 shares by promoters Umang Ketan Mehta and Jinesh Rasiklal Sheth, as per the draft red herring prospectus.

The net proceeds will be used for funding the following objectives:

  • Investment in Altra Agro-Chem Pvt Ltd
  • Investment in Altra Pharma-Chem Pvt Ltd
  • Repayment of certain borrowing availed by the company
  • General corporate purposes

"Our company expects to receive the benefits of listing of the equity shares on the stock exchanges and enhancement of our company’s visibility and brand name amongst our existing and potential customers and creation of a public market for our equity shares in India," according to the DRHP.

The company will reserve 50% of the net offer for qualified institutional buyers, 35% for retail investors and 15% for non-institutional investors.

Marwadi Chandarana Intermediaries Brokers and SMC Capitals are the issue's book-running lead managers, while KFin Technologies is the registrar.

The firm's shares will be listed on the National Stock Exchange (NSE) and the BSE.

Ujin Pharma is involved in distribution and supply of a diversified portfolio of speciality chemicals, solvents, acids, monomers, pharmaceutical raw materials and nutraceuticals.

With more than two decades of operational experience in the chemical sector, it has developed sourcing relationships with international and domestic suppliers, allowing it to procure various chemical products and supply them to traders, distributors and customers operating across multiple end-use industries.

Its products are supplied to customers operating in agrochemical, pharmaceutical, petrochemical, specialty chemical, industrial and automotive sectors, as well as printing inks, paints and coatings and packaging applications.

About The Author

Journalist Kamal Joshi, former Republic TV and latestly news editor, currently associated with Upstox as senior ipo writer.
Kamal Joshi is a business journalist who covers markets and IPOs. He places a special focus on in-depth analysis of DRHPs, RHPs and public-issue documents to produce data-driven stories. He covers trends across mainboard and SME IPOs, anchor allocations, subscription status and post-listing performance. He is passionate about breaking news and enjoys playing pickleball, especially flexing his net play. He was previously associated with Republic TV and LatestLY.

Next Story